Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMETHYST trial of recombinant Timothy grass pollen immunotherapy in allergic rhinoconjunctivitis
2007-003208-37Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Sep 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rPhleum in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergopharma. Primary endpoint: Change in Rhinoconjunctivitis Symptom Medication Score. Started Sep 2007; status: completed.
02
Drugs
rPhleum
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2007-003208-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003208-37.